Baihua Pharmaceutical (600721.SH): Does not involve the research and development of innovative drugs.

Zhitong Finance APP News, Baihua Pharmaceutical (600721.SH) issued a stock trading risk warning announcement stating that the company is a CRO enterprise primarily engaged in the research and development of small-molecule chemical generics. Its main business is to provide customers with "one-stop" full-process services for drug research and registration, primarily focusing on small-molecule generics. The main research projects mostly come from client commissions as well as some self-initiated projects by the company, and do not involve innovative drug development.